CXCL5 and neoplasm: Our results showed that bevacizumab induced FAPα expression in HSCs through the fibroblast growth factor–binding protein 1 (FGFBP1)/FGF2/FGFR1/ERK1/-2/EGR1 axis and FAPα-promoted secretion of CXCL5 in HSCs, which activated CXCR2 to enhance myeloid-derived suppressor cell (MDSC) infiltration and tumor cell EMT to promote vessel co-option.